Human / Cynomolgus / Rhesus macaque ROR1 Protein, His Tag (MALS verified)
分子別名(Synonym)
ROR1,NTRKR1
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human / Cynomolgus / Rhesus macaque ROR1, His Tag (RO1-H522y) is expressed from human 293 cells (HEK293). It contains AA Gln 30 - Glu 403 (Accession # Q01973-1). In the region Gln 30 - Glu 403, the AA sequence of Human, Cynomolgus and Rhesus macaque ROR1 are homologus.
Predicted N-terminus: Gln 30
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 43.9 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 30 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
背景(Background)
酪氨酸蛋白激酶跨膜受體ROR1也稱(chēng)為神經(jīng)營(yíng)養(yǎng)性酪氨酸激酶受體相關(guān)1(NTRKR1),屬于蛋白激酶超家族或tyr蛋白激酶家族或ROR亞家族。ROR1包含1個(gè)FZ(卷曲)結(jié)構(gòu)域,1個(gè)Ig樣C2型(免疫球蛋白樣)結(jié)構(gòu)域,1個(gè)kringle結(jié)構(gòu)域,1個(gè)蛋白激酶結(jié)構(gòu)域。ROR1在早期胚胎發(fā)育過(guò)程中高水平表達(dá)。表達(dá)水平在第16天左右強(qiáng)烈下降,成人組織中只有非常低的水平。ROR1可以與酪蛋白激酶1ε(CK1ε)相互作用,激活磷酸肌醇3激酶介導(dǎo)的AKT磷酸化和cAMP反應(yīng)元件結(jié)合蛋白(CREB),這與增強(qiáng)的腫瘤細(xì)胞生長(zhǎng)有關(guān)。
關(guān)鍵字: ROR1;ROR1蛋白;ROR1重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。